GlassScriptPhysician profile
Heather A Collins
NPI 1497750905
$13,377.06
in general payments reported to CMS, 2019-2025
45 companies · $2,077 in 2025
The $2,077 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $1,618 · 2021: $1,751 · 2022: $1,757 · 2023: $2,651 · 2024: $2,333 · 2025: $2,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,062.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,612.52 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $1,396.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,320.80 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,313.16 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $981.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $574.28 | 2019-2025 | Belsomra, Steglatro, Lagevrio |
| Lilly USA, LLC | $551.69 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $482.71 | 2022-2025 | |
| Abbott Laboratories | $400.09 | 2019-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $352.21 | 2023-2025 | Auvelity, Symbravo |
| Janssen Pharmaceuticals, INC | $335.80 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.87 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $280.36 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $253.48 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $242.60 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.